|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: DIOVAN
Summary for Tradename: DIOVAN
|
|
Latest news for DIOVANEuropean Medicines Agency Starts Review of Combined Use Of Drugs That Block The Renin-Angiotensin System20 May 2013, 5:34 pm Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans20 May 2013, 1:47 pm Novartis posts profit gain thanks to new drugs27 April 2013, 11:28 am U.S. Joins Shepherd, Finkelman, Miller & Shah, LLP Whistleblower Lawsuit Against Novartis Pharmaceuticals Corporation26 April 2013, 4:56 pm Novartis posts 6.7 per cent net profit gain in first quarter on drug launches, approvals24 April 2013, 3:27 pm Novartis Boosted by Drug Launches24 April 2013, 7:06 am Novartis seeks productivity improvements with Harry Kirsch as new CFO24 April 2013, 2:28 am Novartis names Harry Kirsch new CFO24 April 2013, 2:13 am Novartis Profit Rises 7% on Lack of Generic Diovan24 April 2013, 1:35 am Courtesy of Yahoo News | ||||||||||||
Clinical Trials for: DIOVANTo Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone Status: Completed Condition: Hypertension; High Blood Pressure Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Status: Active, not recruiting Condition: Proteinuric Kidney Disease; Diabetic Nephropathy; Hypertensive Nephrosclerosis; IgA Nephropathy; Focal Segmental Glomerulosclerosis; Glomerulopathy (Obesity-associated); Glomerulonephritis, Membranous Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Status: Completed Condition: Essential Hypertension Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension Status: Recruiting Condition: Hypertension Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension Status: Completed Condition: Hypertension Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan Status: Completed Condition: Hypertension; Hyperlipidemia Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension Status: Completed Condition: Hypertension ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria Status: Completed Condition: Hypertension; Diabetes Mellitus, Type 2; Albuminuria Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus Status: Completed Condition: Hypertension Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications Status: Completed Condition: Diabetes Mellitus, Type 2 Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | DIOVAN | valsartan | CAPSULE; ORAL | 020665 | Dec 23, 1996 | DISCN | No | 5,399,578*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | DIOVAN | valsartan | TABLET; ORAL | 021283 | Aug 14, 2002 | RX | No | 5,399,578*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | DIOVAN | valsartan | TABLET; ORAL | 021283 | Aug 14, 2002 | RX | No | 5,972,990*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | DIOVAN | valsartan | TABLET; ORAL | 021283 | Aug 14, 2002 | RX | No | 6,294,197*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: DIOVAN
| Drugname | Dosage | Strength | RLD | Submissiondate |
| valsartan and hydrochlorothiazide | Tablets | 320 mg/12.5 mg and 320 mg/25 mg | Diovan HCT | 2/7/2007 |
| valsartan and hydrochlorothiazide | Tablets | 80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mg | Diovan HCT | 12/2/2005 |
| valsartan | Tablets | 40 mg, 80 mg,160 mg | Diovan | 12/28/2004 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc